Skip to main content
. 2021 Jul 29;36(1):68–79. doi: 10.1038/s41375-021-01346-7

Fig. 4. Igf2bp3 deletion is necessary for MLL-Af4 leukemia-initiating cells to reconstitute mice in vivo.

Fig. 4

a Percentage of CD45.2+ in the peripheral blood of secondary transplanted mice from leukemic WT/MLL-Af4 or I3KO/MLL-Af4 donor mice at 106, 105, and 104 BM cells at 4 weeks post transplantation (For all panels in this figure: n = 6 recipient mice per genotype for 106 cells and  n = 10  recipient mice per genotype for 105 and 104 cells; t test; *P < 0.05, ***P < 0.001, ****P < 0.0001). b WBC from PB of secondary transplanted mice from WT/MLL-Af4 or I3KO/MLL-Af4 BM 3–4 weeks post transplant (t test; **P < 0.01). c Splenic weights of secondary transplanted mice at 4–5 weeks (t test; *P < 0.05, ***P < 0.001, ****P < 0.0001). d Images of splenic tumors in secondary mice transplanted with 10,000 BM cells from WT/MLL-Af4 mice (left) or I3KO/MLL-Af4 mice (right) at 5 weeks. e H&E staining of liver and spleen of secondary transplant recipients that received 105 cells at 4 weeks. Scale bar: liver, 200 μm; spleen, 100 μm; CV central vein, W white pulp, R red pulp, Leu leukemia; arrows showing infiltration.